Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.

Circosta P, Vitaggio K, Elia AR, Todorovic M, Sangiolo D, Carnevale-Schianca F, Vallario A, Geuna M, Aglietta M, Cignetti A.

Immunotherapy. 2018 Jul;10(9):753-767. doi: 10.2217/imt-2017-0139.

PMID:
30008257
2.

Next generation immune-checkpoints for cancer therapy.

Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D.

J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. Review.

3.

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.

Peraldo-Neia C, Ostano P, Cavalloni G, Pignochino Y, Sangiolo D, De Cecco L, Marchesi E, Ribero D, Scarpa A, De Rose AM, Giuliani A, Calise F, Raggi C, Invernizzi P, Aglietta M, Chiorino G, Leone F.

BMC Genomics. 2018 Jun 5;19(1):440. doi: 10.1186/s12864-018-4829-0.

4.

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D.

Oncoimmunology. 2018 Feb 15;7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. eCollection 2018.

5.

BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.

Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2018 Jul 15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12.

PMID:
29650750
6.

Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, Grignani G, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D.

Mol Med. 2017 Aug 9;23. doi: 10.2119/molmed.2017.00084. [Epub ahead of print]

7.

Treating breast cancer with cell-based approaches: an overview.

Gallo S, Sangiolo D, Carnevale Schianca F, Aglietta M, Montemurro F.

Expert Opin Biol Ther. 2017 Oct;17(10):1255-1264. doi: 10.1080/14712598.2017.1356816. Epub 2017 Jul 20. Review.

PMID:
28728493
8.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G.

Mol Cancer. 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5.

9.

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G.

Eur J Cancer. 2017 Jun;78:122-132. doi: 10.1016/j.ejca.2017.03.025. Epub 2017 Apr 24.

PMID:
28448856
10.

Treatment of metastatic melanoma: a multidisciplinary approach.

Fava P, Astrua C, Sanlorenzo M, Ribero S, Brizio M, Filippi AR, Marra E, Picciotto F, Sangiolo D, Carnevale-Schianca F, Aglietta M, Sandrucci S, Ricardi U, Caliendo V, Quaglino P, Fierro MT.

G Ital Dermatol Venereol. 2017 Jun;152(3):241-261. doi: 10.23736/S0392-0488.17.05633-4. Epub 2017 Mar 14. Review.

PMID:
28290625
11.

Role of interferon in melanoma: old hopes and new perspectives.

Sanlorenzo M, Vujic I, Carnevale-Schianca F, Quaglino P, Gammaitoni L, Fierro MT, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2017 Apr;17(4):475-483. doi: 10.1080/14712598.2017.1289169. Epub 2017 Feb 16. Review. Erratum in: Expert Opin Biol Ther. 2018 Mar;18(3):1.

PMID:
28274138
12.

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M.

Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466. doi: 10.1016/j.bbmt.2016.12.636. Epub 2016 Dec 27.

13.

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.

Comunanza V, Corà D, Orso F, Consonni FM, Middonti E, Di Nicolantonio F, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F.

EMBO Mol Med. 2017 Feb;9(2):219-237. doi: 10.15252/emmm.201505774.

14.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.

15.

Adoptive immunotherapy against ovarian cancer.

Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G.

J Ovarian Res. 2016 May 17;9(1):30. doi: 10.1186/s13048-016-0236-9. Review.

16.

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.

Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D.

J Transl Med. 2016 May 5;14(1):119. doi: 10.1186/s12967-016-0872-2.

17.

Redirected T cells in cancer therapy.

Sangiolo D.

Expert Opin Biol Ther. 2015;15(12):1667-70. doi: 10.1517/14712598.2015.1096340. Epub 2015 Oct 29.

PMID:
26515608
18.

Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.

Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D.

Immunotherapy. 2015;7(9):999-1010. doi: 10.2217/imt.15.61. Epub 2015 Aug 27. Review.

PMID:
26310715
19.

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

Sanlorenzo M, Vujic I, Moy A, Quaglino P, Fierro MT, Gammaitoni L, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2015;15(10):1491-500. doi: 10.1517/14712598.2015.1069272. Epub 2015 Jul 24. Review.

20.

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM.

BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1.

21.

Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.

Elia AR, Circosta P, Sangiolo D, Bonini C, Gammaitoni L, Mastaglio S, Genovese P, Geuna M, Avolio F, Inghirami G, Tarella C, Cignetti A.

Hum Gene Ther. 2015 Apr;26(4):220-31. doi: 10.1089/hum.2014.112. Epub 2015 Apr 13.

PMID:
25758764
22.

Adoptive immunotherapy against sarcomas.

Mesiano G, Leuci V, Giraudo L, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, Capellero S, Pignochino Y, Grignani G, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2015 Apr;15(4):517-28. doi: 10.1517/14712598.2015.987121. Epub 2014 Dec 16. Review.

PMID:
25516119
23.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group.

Lancet Oncol. 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11.

24.

Recent advances in the development of breast cancer vaccines.

Milani A, Sangiolo D, Aglietta M, Valabrega G.

Breast Cancer (Dove Med Press). 2014 Oct 14;6:159-68. doi: 10.2147/BCTT.S38428. eCollection 2014. Review.

25.

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma.

Sangiolo D, Mesiano G, Gammaitoni L, Aglietta M, Grignani G.

Oncoimmunology. 2014 Mar 17;3:e28269. eCollection 2014.

26.

Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.

Gammaitoni L, Leuci V, Mesiano G, Giraudo L, Todorovic M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2014 Sep;14(9):1259-70. doi: 10.1517/14712598.2014.918099. Epub 2014 May 16. Review.

27.

Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.

Leuci V, Mesiano G, Gammaitoni L, Aglietta M, Sangiolo D.

Curr Gene Ther. 2014 Feb;14(1):52-62. Review.

28.

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.

Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'Aglio C, D'Ambrosio L, Pisacane A, Sarotto I, Miano S, Ferrero I, Carnevale-Schianca F, Pignochino Y, Sassi F, Bertotti A, Piacibello W, Fagioli F, Aglietta M, Grignani G.

Cancer Res. 2014 Jan 1;74(1):119-29. doi: 10.1158/0008-5472.CAN-13-1559. Epub 2013 Dec 19.

29.

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.

Leuci V, Mesiano G, Gammaitoni L, Todorovic M, Giraudo L, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Anticancer Agents Med Chem. 2014 Feb;14(2):211-22. Review.

30.

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.

Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, Caravelli D, Giacone E, Venesio T, Balsamo A, Pignochino Y, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2013 Aug 15;19(16):4347-58. doi: 10.1158/1078-0432.CCR-13-0061. Epub 2013 Jun 21.

31.

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G.

Ann Oncol. 2013 Jul;24(7):1740-8. doi: 10.1093/annonc/mdt133. Epub 2013 Apr 12. Review.

PMID:
23585514
32.

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G.

Clin Cancer Res. 2013 Apr 15;19(8):2117-31. doi: 10.1158/1078-0432.CCR-12-2293. Epub 2013 Feb 22.

33.

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.

Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D.

J Immunother. 2012 Sep;35(7):579-86.

PMID:
22892454
34.

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2012 Jun;12(6):673-84. doi: 10.1517/14712598.2012.675323. Epub 2012 Apr 14. Review.

PMID:
22500889
35.

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.

Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M, Jordaney N, Circosta P, Elia A, Lesnikova M, Georges GE, Piacibello W, Fagioli F, Cignetti A, Aglietta M, Sangiolo D.

J Biotechnol. 2011 Dec 10;156(3):218-26. doi: 10.1016/j.jbiotec.2011.09.001. Epub 2011 Sep 10.

PMID:
21933686
36.
37.

Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?

Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, Sangiolo D, Fizzotti M, Caravelli D, Capaldi A, Anselmetti G, Palesandro E, D'Ambrosio L, Coha V, Obert R, Aglietta M, Grignani G.

J Clin Oncol. 2011 Aug 20;29(24):e691-3. doi: 10.1200/JCO.2011.35.6733. Epub 2011 Jun 27. No abstract available.

38.

Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks.

Sangiolo D, Leuci V, Gallo S, Aglietta M, Piacibello W.

Expert Opin Biol Ther. 2011 May;11(5):655-66. doi: 10.1517/14712598.2011.565325. Epub 2011 Mar 7. Review.

PMID:
21375466
39.

Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.

Sangiolo D, Storb R, Deeg HJ, Flowers ME, Martin PJ, Sandmaier BM, Kiem HP, Nash RA, Doney K, Leisenring WM, Georges GE.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1411-8. doi: 10.1016/j.bbmt.2010.04.005. Epub 2010 Apr 18.

40.

Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene.

Leuci V, Gammaitoni L, Capellero S, Sangiolo D, Mesuraca M, Bond HM, Migliardi G, Cammarata C, Aglietta M, Morrone G, Piacibello W.

Stem Cells. 2009 Nov;27(11):2815-23. doi: 10.1002/stem.224.

41.

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, Sangiolo D, Todorovic M, Giachino C, Cignetti A.

Hum Gene Ther. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117.

PMID:
19678763
42.

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.

Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A.

Expert Opin Biol Ther. 2009 Jul;9(7):831-40. doi: 10.1517/14712590903005552. Review.

PMID:
19463075
43.

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.

Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A.

Int Immunol. 2008 Jul;20(7):841-8. doi: 10.1093/intimm/dxn042. Epub 2008 May 9.

PMID:
18469328
44.

Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection.

Sangiolo D, Lesnikova M, Nash RA, Jensen MC, Nikitine A, Kiem HP, Georges GE.

Gene Ther. 2007 Nov;14(21):1549-54. Epub 2007 Sep 6.

PMID:
17805303
45.

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, Rota-Scalabrini D, Geuna M, Fizzotti M, Sangiolo D, Sottile A, De Rosa G, Bucci AR, Lambertenghi-Deliliers G, Benedetti E, Nash R, Aglietta M.

Blood. 2006 May 1;107(9):3795-803. Epub 2006 Jan 10.

46.

Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.

Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M, Hackman RC, Boeckh M.

Biol Blood Marrow Transplant. 2005 Jul;11(7):521-9.

47.

Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.

Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7.

Supplemental Content

Loading ...
Support Center